<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833690</url>
  </required_header>
  <id_info>
    <org_study_id>INO-PD-P2-2008</org_study_id>
    <nct_id>NCT00833690</nct_id>
  </id_info>
  <brief_title>Safety of Urate Elevation in Parkinson's Disease</brief_title>
  <acronym>SURE-PD</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Parkinson Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Parkinson Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of inosine and its
      ability to raise urate levels in blood and cerebral spinal fluid in individuals with early
      Parkinson disease. This will determine whether it is appropriate to proceed with a larger
      study of inosine's ability to modify the rate of disability progression in PD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background &amp; Rationale:

      Convergent epidemiological and clinical observations have identified urate - a major
      antioxidant and the end product of purine metabolism in humans - as the first molecular
      predictor of both the risk and the progression of typical Parkinson's disease (PD). Among
      some 1600 early PD patients enrolled in prior clinical trials, those with baseline serum
      urate levels in the highest quintile (i.e., in the upper normal range) displayed a 40% slower
      rate of clinical (disability) progression compared to those with baseline urate at or below
      the median (with p&lt;0.000001 for trend across quintiles). Similarly, amongst those who
      underwent serial SPECT brain scans for changes in dopamine transporter (DAT) binding, those
      with higher baseline serum urate levels displayed a slower rate of radiographic progression
      (loss of striatal DAT). Moreover, urate levels in baseline cerebrospinal fluid (CSF) samples
      also correlate inversely with rates of clinical progression. Although this link between urate
      and a slower decline in PD appears reproducible and robust, the critical question of
      causality remains to be answered by a well-designed clinical trial. The biological
      plausibility of neuroprotection by urate strengthens the rationale for expedient pursuit of a
      trial. The availability of established pharmacological approaches to elevating urate makes
      such a trial feasible. In particular, inosine, an orally bioavailable, central nervous system
      (CNS)-penetrant purine precursor of urate, offers a practical strategy as it can readily
      elevate serum urate, has been widely consumed as a nutritional supplement, and has been
      administered chronically in several multi-year clinical trials for multiple sclerosis. Before
      embarking on a neuroprotection trial of inosine for PD, careful assessment of the safety,
      validity and methodology of this approach in PD patients is warranted.

      Specific Aims:

      The main goal of the study is to determine whether inosine is suitable for phase III
      evaluation of its ability to modify the rate of disability progression in PD. Specific
      primary aims entail the determination of the safety and tolerability of oral inosine, and its
      ability to elevate urate levels in serum or CSF; and the selection of an optimal dosing
      regimen. Secondary aims entail the further optimization of a possible phase III study design.

      Methods:

      A placebo-controlled double-blind dose-ranging randomized trial of inosine will be conducted
      in early PD. Ninety untreated subjects diagnosed with idiopathic PD and with a serum urate
      below the population mean (~6 mg/dL) will be enrolled at 17 North American sites and
      randomized to one of three treatment groups (n=30): 1) placebo, 2) inosine dosed to produce a
      mild elevation in serum urate, and 3) inosine dosed to produce a moderate elevation.
      Tolerability, validity (urate elevation), dosage and symptomatic efficacy will be assessed
      after 12 weeks of treatment. Contingent on adequate tolerability and validity as assessed in
      this short-term analysis, the study will continue for 2 years total duration with 2 groups
      (placebo and a merged single inosine dosing group) or the original 3 to assess long-term
      tolerability and safety, which will focus on main known risks of urolithiasis and gouty
      arthritis and the theoretical risk of cardiovascular disease.

      Significance:

      This study will determine whether a phase III trial of inosine as a potential neuroprotectant
      in PD is warranted. If it is, then the present study could shorten substantially the lead
      time, and through optimization of key design features would enhance the likelihood of its
      safety and success.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as the extent to which assigned treatment could continue without prolonged dose reduction (&gt;48 consecutive days or &gt;73 cumulative days, which is 10% of total 2-year follow-up) due to adverse experiences (AEs), and was assessed after 6 and 24 months on study drug. Units of measure are percentage points (i.e., % of participants in the group).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the extent to which assigned treatment could continue without prolonged dose reduction (&gt;48 consecutive days or &gt;73 cumulative days, which is 10% of total 2-year follow-up) due to AEs, and was assessed after 6 and 24 months on study drug. Units of measure are percentage points (i.e., % of participants in the group).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as absence of serious adverse experiences (SAEs) that warranted terminating an inosine treatment arm or the trial, as determined by the Data and Safety Monitoring Committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSF Urate (All Patients)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Urate concentration in cerebrospinal fluid (CSF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Urate (Females)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Urate (Males)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Urate as a Proportion of Baseline Serum Urate (All Patients)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Urate as a Proportion of Baseline Serum Urate (Females)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Urate as a Proportion of Baseline Serum Urate (Males)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Screening Visits, up to 45 days prior to Baseline Visit. Specifically, Screening Visit 1 occurred between day -45 and -4; Screening Visit 2 occurred between day -43 and -2.</time_frame>
    <description>From blood sample drawn prior to enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Baseline Visit</time_frame>
    <description>From blood sample drawn prior to enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 01 (Week 2; 14 +/- 3 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 02 (Week 4; 28 +/- 3 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 03 (Week 6; 42 +/- 3 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 04 (Week 9; 63 +/- 5 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 05 (Week 12; 84 +/- 7 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn before taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 06 (Month 6; 180 +/- 7 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 07 (Month 9; 270 +/- 7 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 08 (Month 12; 360 +/- 7 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 09 (Month 15; 450 +/- 7 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 10 (Month 18; 540 +/- 7 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 11 (Month 21; 630 +/- 7 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Visit 12 (Month 24; 720 +/- 7 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>End of Study Drug Visit (ESD) (Month 9-24; 263-727 days after Baseline Visit)</time_frame>
    <description>From blood sample drawn after taking study drug that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>Safety Visit (SV); 30 +/- 3 days following ESD or Month 24 Visit</time_frame>
    <description>From blood sample drawn a month after stopping study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 01 from Baseline (i.e., between -45 days and +2 weeks)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 02 from Baseline (i.e., between -45 days and +4 weeks)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 03 from Baseline (i.e., between -45 days and +6 weeks)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 04 from Baseline (i.e., between -45 days and +9 weeks)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 05 from Baseline (i.e., between -45 days and +12 weeks)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 06 from Baseline (i.e., between -45 days and +6 months)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 07 from Baseline (i.e., between -45 days and +9 months)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 08 from Baseline (i.e., between -45 days and +12 months)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 09 from Baseline (i.e., between -45 days and +15 months)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 10 from Baseline (i.e., between -45 days and +18 months)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 11 from Baseline (i.e., between -45 days and +21 months)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Visit 12 from Baseline (i.e., between -45 days and +24 months)</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Safety Visit (SV) from Baseline (i.e., between -45 days and +760 days [+1 month after ESD Visit])</time_frame>
    <description>Change from an Average of Baseline and Screening Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Urate</measure>
    <time_frame>Safety Visit (SV) from End of Study Drug Visit (ESD); i.e., between +263 and +760 days)</time_frame>
    <description>Change from Last Visit on Study Drug</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>[A:]</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to produce no urate elevation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[B:]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inosine to produce a mild urate elevation
500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[C.]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inosine to produce a moderate urate elevation
500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms</description>
    <arm_group_label>[A:]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inosine</intervention_name>
    <description>500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL</description>
    <arm_group_label>[B:]</arm_group_label>
    <other_name>hypoxanthine 9-β-D-ribofuranoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inosine</intervention_name>
    <description>500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL</description>
    <arm_group_label>[C.]</arm_group_label>
    <other_name>hypoxanthine 9-β-D-ribofuranoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic PD with at least two of the cardinal signs of PD (resting tremor,
             bradykinesia, rigidity)

          -  Currently not taking or needing any treatment for PD other than an monoamine oxidase-B
             (MAO-B) inhibitor

          -  Age 30 or older at the time of PD diagnosis

          -  Diagnosis of PD made within past 3 years

          -  Serum urate ≤ 5.8 mg/dL at initial screening

        Exclusion Criteria:

          -  History of kidney stones, gout, stroke, or heart attack

          -  History of renal disease or certain cardiovascular problems within the past year

          -  Acidic urine (pH ≤ 5.0), uric acid, or urate crystalluria at screening

          -  Use of certain medications including co-enzyme Q, creatine, more than 50 IU of vitamin
             E daily, and more than 300 mg of vitamin C daily. (A standard daily multivitamin is
             permitted.)

          -  Use of anti-PD and other medications targeting central nervous system dopamine
             transmission

          -  Known unstable medical or psychiatric condition that may compromise participation in
             the study

          -  Women who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Schwarzschild, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Neurology Specialists, LLC</name>
      <address>
        <city>Manchester</city>
        <state>Connecticut</state>
        <zip>06040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struthers Parkinson's Center</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butler Hospital Movement Disorder Program</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.Parkinson-Study-Group.org</url>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2009</study_first_posted>
  <results_first_submitted>December 26, 2013</results_first_submitted>
  <results_first_submitted_qc>May 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2014</results_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Parkinson Study Group</investigator_affiliation>
    <investigator_full_name>Michael Schwarzschild</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Parkinson disease</keyword>
  <keyword>PD</keyword>
  <keyword>inosine</keyword>
  <keyword>urate</keyword>
  <keyword>uric acid</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>[A:]Placebo</title>
          <description>Placebo to produce no urate elevation</description>
        </group>
        <group group_id="P2">
          <title>[B:]Mild</title>
          <description>Inosine to produce a mild urate elevation</description>
        </group>
        <group group_id="P3">
          <title>[C.]Moderate</title>
          <description>Inosine to produce a moderate urate elevation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued study drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>[A:]Placebo</title>
          <description>Placebo to produce no urate elevation</description>
        </group>
        <group group_id="B2">
          <title>[B:]Mild</title>
          <description>Inosine to produce a mild urate elevation</description>
        </group>
        <group group_id="B3">
          <title>[C.]Moderate</title>
          <description>Inosine to produce a moderate urate elevation</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="11"/>
                    <measurement group_id="B2" value="62" spread="10"/>
                    <measurement group_id="B3" value="62" spread="11"/>
                    <measurement group_id="B4" value="62" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years since symptom onset</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="1.3"/>
                    <measurement group_id="B2" value="2.8" spread="1.9"/>
                    <measurement group_id="B3" value="2.2" spread="2.0"/>
                    <measurement group_id="B4" value="2.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years since diagnosis</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="1.3"/>
                    <measurement group_id="B2" value="1.3" spread="1.0"/>
                    <measurement group_id="B3" value="0.6" spread="0.7"/>
                    <measurement group_id="B4" value="1.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Urate</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="0.7"/>
                    <measurement group_id="B2" value="4.3" spread="1.2"/>
                    <measurement group_id="B3" value="4.6" spread="0.9"/>
                    <measurement group_id="B4" value="4.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum urate in women</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" spread="0.8"/>
                    <measurement group_id="B2" value="3.9" spread="1.3"/>
                    <measurement group_id="B3" value="4.4" spread="0.8"/>
                    <measurement group_id="B4" value="4.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum urate in men</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="0.5"/>
                    <measurement group_id="B2" value="5.0" spread="0.8"/>
                    <measurement group_id="B3" value="4.9" spread="0.9"/>
                    <measurement group_id="B4" value="4.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>United Parkinson's Disease Rating Scale (UPDRS) score total</title>
          <description>The UPDRS is designed to monitor disability and impairment due to Parkinson's disease. It comprises several parts. Part I evaluates &quot;Mentation, Behavior, and Mood&quot; (with a maximum of 16 points; more points are worse); Part II evaluates &quot;Activities of Daily Living&quot; (with a maximum of 52 points); Part III entails a &quot;Motor Examination&quot; (with a maximum of 108 points). Total score of Parts I-III sums the points from all parts and thus can range from a minimum of 0 (best) to a maximum of 176 (worst).</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="10"/>
                    <measurement group_id="B2" value="20" spread="9"/>
                    <measurement group_id="B3" value="21" spread="10"/>
                    <measurement group_id="B4" value="22" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montreal Cognitive Assessment (MoCA)</title>
          <description>The MoCA assesses short term and working memory, visual-spatial abilities, executive function, attention, concentration, language and orientation. The total score ranges from 0 to 30 (highest function).</description>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="1.9"/>
                    <measurement group_id="B2" value="28" spread="1.8"/>
                    <measurement group_id="B3" value="28" spread="2.0"/>
                    <measurement group_id="B4" value="28" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geriatric Depression Scale-short form (GDS-S)</title>
          <description>GDS-S is a short 15 'yes/no' question instrument for assessing depression in older adults. Questions are answered by the research participant (i.e., self-rater). Scores range range from 0 to 15 and higher scores represent greater depression. Scores of 5-9 and &gt;9 have been correlated with mild and moderate-severe depression, respectively.</description>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" spread="1.9"/>
                    <measurement group_id="B2" value="1.4" spread="1.7"/>
                    <measurement group_id="B3" value="1.8" spread="2.6"/>
                    <measurement group_id="B4" value="1.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability</title>
        <description>Defined as the extent to which assigned treatment could continue without prolonged dose reduction (&gt;48 consecutive days or &gt;73 cumulative days, which is 10% of total 2-year follow-up) due to adverse experiences (AEs), and was assessed after 6 and 24 months on study drug. Units of measure are percentage points (i.e., % of participants in the group).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability</title>
          <description>Defined as the extent to which assigned treatment could continue without prolonged dose reduction (&gt;48 consecutive days or &gt;73 cumulative days, which is 10% of total 2-year follow-up) due to adverse experiences (AEs), and was assessed after 6 and 24 months on study drug. Units of measure are percentage points (i.e., % of participants in the group).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability</title>
        <description>Defined as the extent to which assigned treatment could continue without prolonged dose reduction (&gt;48 consecutive days or &gt;73 cumulative days, which is 10% of total 2-year follow-up) due to AEs, and was assessed after 6 and 24 months on study drug. Units of measure are percentage points (i.e., % of participants in the group).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability</title>
          <description>Defined as the extent to which assigned treatment could continue without prolonged dose reduction (&gt;48 consecutive days or &gt;73 cumulative days, which is 10% of total 2-year follow-up) due to AEs, and was assessed after 6 and 24 months on study drug. Units of measure are percentage points (i.e., % of participants in the group).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Urate (All Patients)</title>
        <description>Urate concentration in cerebrospinal fluid (CSF)</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Urate (All Patients)</title>
          <description>Urate concentration in cerebrospinal fluid (CSF)</description>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427" spread="190"/>
                    <measurement group_id="O2" value="544" spread="148"/>
                    <measurement group_id="O3" value="594" spread="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Urate (Females)</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Urate (Females)</title>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285" spread="69"/>
                    <measurement group_id="O2" value="517" spread="169"/>
                    <measurement group_id="O3" value="575" spread="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Urate (Males)</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Urate (Males)</title>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="546" spread="178"/>
                    <measurement group_id="O2" value="586" spread="113"/>
                    <measurement group_id="O3" value="619" spread="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Urate as a Proportion of Baseline Serum Urate (All Patients)</title>
        <description>Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Urate as a Proportion of Baseline Serum Urate (All Patients)</title>
          <description>Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12).</description>
          <units>percentage of baseline serum urate</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="4.0"/>
                    <measurement group_id="O2" value="13.1" spread="4.0"/>
                    <measurement group_id="O3" value="13.4" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Urate as a Proportion of Baseline Serum Urate (Females)</title>
        <description>Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Urate as a Proportion of Baseline Serum Urate (Females)</title>
          <description>Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12).</description>
          <units>percentage of baseline serum urate</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="1.8"/>
                    <measurement group_id="O2" value="13.5" spread="5.0"/>
                    <measurement group_id="O3" value="13.3" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Urate as a Proportion of Baseline Serum Urate (Males)</title>
        <description>Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Urate as a Proportion of Baseline Serum Urate (Males)</title>
          <description>Although CSF urate was not measured at baseline, the change of CSF urate from baseline may be indirectly estimated by the ratio of CSF urate (at the 12 week visit when a lumbar puncture was performed) to the serum urate measured in the same subject at baseline. Baseline serum urate and CSF urate concentrations are directly correlated with one another (i.e., individuals with higher serum urate concentrations tend to have higher CSF urate concentrations) even though the concentration of urate in CSF is typically ~10% of that in serum. The ratio of CSF urate to baseline serum urate can be expressed as the percentage of the value of urate concentration measured in serum at baseline that is measured in CSF (at week 12).</description>
          <units>percentage of baseline serum urate</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="3.8"/>
                    <measurement group_id="O2" value="12.4" spread="2.2"/>
                    <measurement group_id="O3" value="13.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn prior to enrollment</description>
        <time_frame>Screening Visits, up to 45 days prior to Baseline Visit. Specifically, Screening Visit 1 occurred between day -45 and -4; Screening Visit 2 occurred between day -43 and -2.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn prior to enrollment</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="0.62"/>
                    <measurement group_id="O2" value="4.28" spread="0.86"/>
                    <measurement group_id="O3" value="4.39" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="0.6"/>
                    <measurement group_id="O2" value="4.4" spread="0.88"/>
                    <measurement group_id="O3" value="4.48" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn prior to enrollment</description>
        <time_frame>Baseline Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn prior to enrollment</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54" spread="0.69"/>
                    <measurement group_id="O2" value="4.32" spread="1.2"/>
                    <measurement group_id="O3" value="4.62" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety</title>
        <description>Defined as absence of serious adverse experiences (SAEs) that warranted terminating an inosine treatment arm or the trial, as determined by the Data and Safety Monitoring Committee.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Defined as absence of serious adverse experiences (SAEs) that warranted terminating an inosine treatment arm or the trial, as determined by the Data and Safety Monitoring Committee.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 01 (Week 2; 14 +/- 3 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="0.65"/>
                    <measurement group_id="O2" value="6.44" spread="1.29"/>
                    <measurement group_id="O3" value="6.93" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 02 (Week 4; 28 +/- 3 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="0.65"/>
                    <measurement group_id="O2" value="6.58" spread="0.87"/>
                    <measurement group_id="O3" value="7.9" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 03 (Week 6; 42 +/- 3 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="0.77"/>
                    <measurement group_id="O2" value="6.69" spread="0.78"/>
                    <measurement group_id="O3" value="7.51" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 04 (Week 9; 63 +/- 5 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" spread="0.58"/>
                    <measurement group_id="O2" value="6.81" spread="1.22"/>
                    <measurement group_id="O3" value="7.62" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn before taking study drug that day</description>
        <time_frame>Visit 05 (Week 12; 84 +/- 7 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn before taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="0.59"/>
                    <measurement group_id="O2" value="5.85" spread="1.02"/>
                    <measurement group_id="O3" value="6.91" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 06 (Month 6; 180 +/- 7 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="1"/>
                    <measurement group_id="O2" value="6.94" spread="1.6"/>
                    <measurement group_id="O3" value="8.27" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 07 (Month 9; 270 +/- 7 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="0.89"/>
                    <measurement group_id="O2" value="6.77" spread="1.51"/>
                    <measurement group_id="O3" value="8.06" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 08 (Month 12; 360 +/- 7 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="0.89"/>
                    <measurement group_id="O2" value="6.87" spread="1.05"/>
                    <measurement group_id="O3" value="7.41" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 09 (Month 15; 450 +/- 7 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" spread="0.69"/>
                    <measurement group_id="O2" value="7.26" spread="0.96"/>
                    <measurement group_id="O3" value="7.64" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 10 (Month 18; 540 +/- 7 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="0.76"/>
                    <measurement group_id="O2" value="7" spread="0.97"/>
                    <measurement group_id="O3" value="7.64" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 11 (Month 21; 630 +/- 7 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.47"/>
                    <measurement group_id="O2" value="7.12" spread="1.21"/>
                    <measurement group_id="O3" value="7.56" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>Visit 12 (Month 24; 720 +/- 7 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="0.99"/>
                    <measurement group_id="O2" value="6.84" spread="0.76"/>
                    <measurement group_id="O3" value="7.19" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn after taking study drug that day</description>
        <time_frame>End of Study Drug Visit (ESD) (Month 9-24; 263-727 days after Baseline Visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn after taking study drug that day</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="0.79"/>
                    <measurement group_id="O2" value="6.48" spread="1.25"/>
                    <measurement group_id="O3" value="7.55" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Urate</title>
        <description>From blood sample drawn a month after stopping study drug</description>
        <time_frame>Safety Visit (SV); 30 +/- 3 days following ESD or Month 24 Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Urate</title>
          <description>From blood sample drawn a month after stopping study drug</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="0.77"/>
                    <measurement group_id="O2" value="4.69" spread="1.28"/>
                    <measurement group_id="O3" value="4.38" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 01 from Baseline (i.e., between -45 days and +2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.41"/>
                    <measurement group_id="O2" value="2.1" spread="0.83"/>
                    <measurement group_id="O3" value="2.44" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 02 from Baseline (i.e., between -45 days and +4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.48"/>
                    <measurement group_id="O2" value="2.24" spread="1.13"/>
                    <measurement group_id="O3" value="3.41" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 03 from Baseline (i.e., between -45 days and +6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.51"/>
                    <measurement group_id="O2" value="2.35" spread="1.03"/>
                    <measurement group_id="O3" value="3.02" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 04 from Baseline (i.e., between -45 days and +9 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.35"/>
                    <measurement group_id="O2" value="2.47" spread="1.34"/>
                    <measurement group_id="O3" value="3.13" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 05 from Baseline (i.e., between -45 days and +12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.42"/>
                    <measurement group_id="O2" value="1.51" spread="0.8"/>
                    <measurement group_id="O3" value="2.42" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 06 from Baseline (i.e., between -45 days and +6 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.86"/>
                    <measurement group_id="O2" value="2.55" spread="1.4"/>
                    <measurement group_id="O3" value="3.78" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 07 from Baseline (i.e., between -45 days and +9 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.68"/>
                    <measurement group_id="O2" value="2.43" spread="1.56"/>
                    <measurement group_id="O3" value="3.56" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 08 from Baseline (i.e., between -45 days and +12 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.78"/>
                    <measurement group_id="O2" value="2.46" spread="1.24"/>
                    <measurement group_id="O3" value="2.96" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 09 from Baseline (i.e., between -45 days and +15 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.67"/>
                    <measurement group_id="O2" value="2.9" spread="0.98"/>
                    <measurement group_id="O3" value="3.19" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 10 from Baseline (i.e., between -45 days and +18 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.43"/>
                    <measurement group_id="O2" value="2.49" spread="1.07"/>
                    <measurement group_id="O3" value="3.26" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 11 from Baseline (i.e., between -45 days and +21 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.59"/>
                    <measurement group_id="O2" value="2.53" spread="1.12"/>
                    <measurement group_id="O3" value="3.11" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Visit 12 from Baseline (i.e., between -45 days and +24 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="1.08"/>
                    <measurement group_id="O2" value="2.22" spread="0.96"/>
                    <measurement group_id="O3" value="2.93" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from an Average of Baseline and Screening Visits</description>
        <time_frame>Safety Visit (SV) from Baseline (i.e., between -45 days and +760 days [+1 month after ESD Visit])</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from an Average of Baseline and Screening Visits</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.62"/>
                    <measurement group_id="O2" value="0.35" spread="0.88"/>
                    <measurement group_id="O3" value="-0.11" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Urate</title>
        <description>Change from Last Visit on Study Drug</description>
        <time_frame>Safety Visit (SV) from End of Study Drug Visit (ESD); i.e., between +263 and +760 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[A:]Placebo</title>
            <description>Placebo to produce no urate elevation</description>
          </group>
          <group group_id="O2">
            <title>[B:]Mild</title>
            <description>Inosine to produce a mild urate elevation</description>
          </group>
          <group group_id="O3">
            <title>[C.]Moderate</title>
            <description>Inosine to produce a moderate urate elevation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Urate</title>
          <description>Change from Last Visit on Study Drug</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.51"/>
                    <measurement group_id="O2" value="-1.8" spread="1.33"/>
                    <measurement group_id="O3" value="-3.2" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>[A:]Placebo</title>
          <description>Placebo to produce no urate elevation</description>
        </group>
        <group group_id="E2">
          <title>[B:]Mild</title>
          <description>Inosine to produce a mild urate elevation</description>
        </group>
        <group group_id="E3">
          <title>[C.]Moderate</title>
          <description>Inosine to produce a moderate urate elevation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Human ehrlichiosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Upper respiratory track infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael A. Schwarzschild, MD, PhD</name_or_title>
      <organization>The Parkinson Study Group</organization>
      <phone>617-724-9611</phone>
      <email>mschwarzschild@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

